The biotech industry experienced its share of stormy weather this year, from budget cuts and the fiscal cliff to Prometheus v. Mayo and a drop in VC funds, but there were a few sunny days here and there: FDA finally issued its draft guidance on the development and approval of biosimilar drugs, and two new obesity drugs were approved by FDA, the first in more than a decade. (For more on all of the above developments, click here.) So, what does your industry forecast look like for 2013—clear sailing ahead, or should sailors take warning?

Poll Question:
What kind of future do you predict for the biotech industry in 2013?

Stormy
97

Cloudy
268

Sunny
224

Previous articleMexico Now Accepting Blood Donations from Gay and Bisexual Men
Next articleBiggest Biotech Trends of 2012